Exhibitors Search
VAXCELL-BIO CO., LTD.
Booth no.
C12/H50
|
Exhibition
|
|KOREA LIFE SCIENCE |
|---|---|
|
Country
|
| Korea, South |
|
Address
|
|98-1 Sandan-gil, Hwasun-eup, Hwasun-gun, Jeonnam-Gwangju, Republic of Korea |
|
Tel
|
|+82-61-373-0046 |
|
Exhibits
|
| NK, CAR cell and gene therapy |
|
Company Type
|
| Pharmaceutical / Drug Development Company , Regenerative Medicine Company , CRO / CMO Company |
Promotional Video Application Upload
Exhibitor Information
Vaxcell-Bio Co., Ltd., founded in 2010 and listed on KOSDAQ in 2020, is a clinical-stage biotech developing cell- and gene-based cancer immunotherapies (NK cell, CAR-T/CAR-MILs) and companion animal biopharmaceuticals. Headquartered in Hwasun, Jeollanam-do, Korea, the company operates its own GMP facility for in-house production of clinical-grade cell therapies. Its lead asset, VCB-1102 (Vax-NK), an autologous NK cell therapy for advanced hepatocellular carcinoma, completed Phase 2a with an objective response rate of 68.75% and median overall survival of 24.05 months, and is being expanded to small cell lung and pancreatic cancer. The pipeline also includes VCB-1201 (BCMA CAR-MILs) for multiple myeloma and VCB-1204 (dual-targeting CAR-T) for solid tumors, both targeting IND submission in 2027. Vaxcell-Bio holds 26 patents worldwide and reported KRW 7.06 billion in revenue and KRW 5.64 billion in R&D spending for FY2025, and is pursuing global licensing and co-development partnerships.
Exhibit Description
Vaxcell-Bio's core technology enables large-scale expansion (avg. 300-fold) and high-purity (>=85%) culture of autologous NK cells. Its lead product, VCB-1102 (Vax-NK), combines NK cell infusion with hepatic arterial infusion chemotherapy (HAIC) to deliver high-dose, high-purity NK cells directly to tumor tissue. In a Phase 2a trial in advanced hepatocellular carcinoma, it achieved a 68.75% objective response rate and 24.05-month median overall survival, and is being expanded to small cell lung and pancreatic cancer. The pipeline also includes VCB-1201 (BCMA CAR-MILs) for multiple myeloma and VCB-1204, a dual-targeting (EphA2/PD-L1) CAR-T for solid tumors, both in preclinical development. Clinical materials are manufactured in-house at Vaxcell-Bio's own GMP facility.
Individual Exhibit/Technology Introduction (Detailed)
-
Product Name : VCB-1102 (Vax-NK)VCB-1102 (Vax-NK) is Vaxcell-Bio's proprietary autologous NK cell therapy. NK cells from a patient's own blood are expanded ~300-fold and cultured to ≥85% purity, then combined with hepatic arterial infusion chemotherapy (HAIC; 5-FU and cisplatin) ? a proprietary method delivering high-dose, high-purity NK cells directly to tumor tissue. In a Phase 2a trial (2024) in advanced hepatocellular carcinoma, it achieved a 68.75% objective response rate, 100% disease control rate, 16.82-month median time to progression, and 24.05-month median overall survival, outperforming standard-of-care regimens. As an autologous therapy, immune rejection risk is minimal, and it combines well with existing treatments. Research is underway to expand into small cell lung and pancreatic cancer.
-
Product Name : VCB-1201 (BCMA CAR-MILs)VCB-1201 is Vaxcell-Bio's BCMA-targeted CAR-MILs (Chimeric Antigen Receptor-Marrow Infiltrating Lymphocytes) cell therapy for multiple myeloma. Unlike conventional CAR-T made from peripheral blood T cells, VCB-1201 uses bone marrow-derived T cells (MILs), which adapt better to the tumor microenvironment, form abundant tumor-antigen-specific memory T cells for multi-antigen recognition, and reduce relapse from antigen escape. The program is in nonclinical development, targeting IND submission to Korea's MFDS in 2027. The global multiple myeloma market is projected to grow from ~USD 21.5B in 2024 to USD 27.7B by 2028 (CAGR 6.2%), with patent expiries for agents like Revlimid and Velcade reshaping competition and opening opportunities for next-generation therapies like VCB-1201.
KYUNGYON EXHIBITION CORP.
